BJP RCPsych Publications
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hunter, R.
Right arrow Articles by Goodwin, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hunter, R.
Right arrow Articles by Goodwin, G. M.

The British Journal of Psychiatry 158: 351-357 (1991)
© 1991 The Royal College of Psychiatrists

Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography

R Hunter, DJ Wyper, J Patterson, MT Hansen and GM Goodwin
MRC Brain Metabolism Unit, Royal Edinburgh Hospital.

The effects of physostigmine on patterns of rCBF in patients with pre- senile Alzheimer's disease were studied using 99mTc-labelled HMPAO SPECT. Regional CBF increased in the left cortex relative to right, with the most significant effect in left frontal and higher frontal regions. Measures of regional brain function, such as SPECT, are an important complement to psychological test batteries in understanding the effects in brain of putative antidementia drugs. SPECT brain imaging could extend our understanding of the action of psychotropic drugs in other major psychiatric illnesses.


This article has been cited by other articles:


Home page
 J. Nucl. Med. Technol.Home page
X. M. Zheng
Detecting Regional Cerebral Blood Flow Changes in Alzheimer's Patients After Milameline Treatment: Activation or Baseline SPECT?
J. Nucl. Med. Technol., September 1, 2002; 30(3): 118 - 122.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
M. S. Mega, I. D. Dinov, L. Lee, S. M. O'Connor, D. M. Masterman, B. Wilen, F. Mishkin, A. W. Toga, and J. L. Cummings
Orbital and Dorsolateral Frontal Perfusion Defect Associated With Behavioral Response to Cholinesterase Inhibitor Therapy in Alzheimer's Disease
J Neuropsychiatry Clin Neurosci, May 1, 2000; 12(2): 209 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. S. Mega, D. M. Masterman, S. M. O'Connor, T. R. Barclay, and J. L. Cummings
The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease
Arch Neurol, November 1, 1999; 56(11): 1388 - 1393.
[Abstract] [Full Text] [PDF]

Home page
 AJGPHome page
J. L. Cummings and C. Back
The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease
Am J Geriatr Psychiatry, May 1, 1998; 6(2): 64S - 78.
[Abstract] [Full Text]

Home page
 J PsychopharmacolHome page
N. Prentice, M. Van Beck, N. J. Dougall, A. P. R. Moffoot, R. E. O'Carroll, G. M. Goodwin, and K. P. Ebmeier
A double-blind, placebo-controlled study of tacrine in patients with Alzheimer's disease using SPET
J Psychopharmacol, January 1, 1996; 10(3): 175 - 181.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1991 The Royal College of Psychiatrists.